The results indicated that the SLC3A2, BSG, SLC7A5, SLC7A6, LCN2, and SLC7A9 genes showed higher expression in brain cancer, adrenocortical cancer, esophageal cancer, lung cancer, colorectal cancer, gallbladder cancer, liver cancer, breast cancer, skin cancer, kidney cancer, and gastric cancer, whereas the SLC3A1 and SLC7A11 genes showed lower expression in these cancer cases (Figure 2B). This evidence concerns the gene LCN2 and breast cancer.